Sentences with phrase «pharmacogenomic gene»
-- search and browse through established pharmacogenomic gene - variant - drug - metabolizer status associations; (2)
http://rd-connect.eu/ Not exact matches
That's why some AD researchers are turning to pharmacogenomics: the study of how genes influence the way we respond to drugs.
Pharmacogenomics — the study of how genes affect responses to drugs — is becoming more important in drug - development research and clinical trials, with a view toward decreasing side effects and increasing the efficiency and efficacy of drugs in patients with the right genetic profiles.
The DrugeVar database, an online database triangulating drugs with genes and pharmacogenomics...
His research interests involve pharmacogenomics for hemoglobinopathies and neuropsychiatric disorders, transcriptional regulation of human fetal globin genes and genotype - phenotype correlation in human genetic disorders.
The process they have followed in order to gather the specific information was to extract from the published literature all pharmacogenomic biomarkers that relate to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved drugs with pharmacogenomic information in their label and make them available in a database that triangulates between drugs, genes and pharmacogenomics biomarkers.
An online resource triangulating drugs with genes and biomarkers for clinical pharmacogenomics.
With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services — in gene discovery, pharmaceuticals, DNA - based diagnostics, pharmacogenomics, in silico discovery tools, bioinformatics and medical decision support systems.
deCODE will apply its expertise in in vitro pharmacogenomics to provide gene expression data in relation to a Wyeth candidate treatment for respiratory disease
deCODE will apply its expertise in in vitro pharmacogenomics to provide gene expression data in relation to a Wyeth candidate treatment for respiratory disease Reykjavik, ICELAND, November 20, 2002 — deCODE genetics (Nasdaq / Nasdaq Europe: DCGN) today announced the...
This section invites manuscripts describing (a) Linkage, association, substitution or positional mapping and epigenetic studies in any species; (b) Validation studies of candidate genes using genetically - engineered mutant model organisms; (c) Studies focused on epistatis and gene - environment interactions; (d) Analysis of the functional implications of genomic sequence variation and aim to attach physiological or pharmacogenomic relevance to alterations in genes or proteins; (e) Studies of DNA copy number variants, non-coding RNA, genome deletions, insertions, duplications and other single nucleotide polymorphisms and their relevance to physiology or pharmacology in humans or model organisms, in vitro or in vivo; and (f) Theoretical approaches to analysis of sequence variation.
For example, it is used to identify correlations between gene sequences and diseases, to predict protein structures from amino acid sequences, to aid in the design of novel drugs, and to tailor treatments to individual patients based on their DNA sequences (pharmacogenomics).
With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing pipeline of products and services — in pharmaceuticals, gene and drug discovery, DNA - based diagnostics, pharmacogenomics, bioinformatics, and clinical trials.
To provide insight on the utility and practicality of implementing a pharmacist - driven pharmacogenomics program in a community pharmacy or primary care setting and to provide a clinical update on common drug - gene implications using clinical case vignettes.
ESHG's Gene - Patenting Guidelines Aim to Protect Innovation and Patient Access Pharmacogenomics Reporter - Apr 30, 2008
Clinical and Regenerative medicine refers to development and implementation of advanced therapeutic approaches that may involve the support of expertise in gene / cell therapy, tissue engineering, pharmacology and pharmacogenomics, development of novel molecular target therapy.